

Anti-NaPi2b/SLC34A2 Antibody (Lifastuzumab vedotin)

Introduction

Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) consisting of a humanized Anti-NaPi2b. Lifastuzumab vedotin is a monoclonal antibody and the antimitotic cytotoxic agent monomethyl auristatin E (MMAE). Lifastuzumab vedotin is used to treat platinum-resistant ovarian cancer.

Product parameters

Alternative Names	NAPI3B, RG-7599
Target Accession	O95436
Target	NaPi2b / SLC34A2
CAS number	1401812-88-1
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	MMAE
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	The drug-to-antibody ratio (DAR) of the Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) is 3.7.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

